The law firm of Wohl & Fruchter LLP is investigating possible violations of federal securities laws by officers and directors of Advaxis, Inc. (Advaxis) (NASDAQ: ADXS).

Advaxis is a clinical stage biotechnology company focused on the development of cancer therapies.

On January 21, 2015, SeekingAlpha published an article alleging that, in a recent presentation, Advaxis misrepresented the tumor response data for its ADXS-HPV compound, thereby overstating the effectiveness of the compound in shrinking tumors. The article also alleges that the Company has misled investors concerning the design of its planned Phase 3 trial.

Following the release of the above article, ADXS shares have fallen over 20% in trading on January 21, 2015.

Persons with relevant information, and ADXS shareholders with questions about this investigation, are invited to contact the attorney below, or our Firm by calling 866.833.6245.

Additional information is available on our website at: http://www.wohlfruchter.com/cases/adxs.

About Wohl & Fruchter

Wohl & Fruchter LLP represents plaintiffs in litigation arising from fraud and other fiduciary breaches by corporate managers, as well as other complex litigation matters. Please visit our website, www.wohlfruchter.com, to learn more about our Firm, or contact one of our partners.

This release may be deemed to constitute attorney advertising.